|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Giannini EG, Farinati F, Ciccarese F,
Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E,
Zoli M, Borzio F, et al: Prognosis of untreated hepatocellular
carcinoma. Hepatology. 61:184–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lai HH, Li CW, Hong CC, Sun HY, Chiu CF,
Ou DL and Chen PS: TARBP2-mediated destabilization of Nanog
overcomes sorafenib resistance in hepatocellular carcinoma. Mol
Oncol. 13:928–945. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma H, Yuan L, Li W, Xu K and Yang L: The
LncRNA H19/miR-193a-3p axis modifies the radio-resistance and
chemotherapeutic tolerance of hepatocellular carcinoma cells by
targeting PSEN1. J Cell Biochem. 119:8325–8335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Lv B, Su Y, Wang X, Bu J and Yao
L: Exosome-mediated transfer of lncRNA HOTTIP promotes cisplatin
resistance in gastric cancer cells by regulating HMGA1/miR-218
axis. Onco Targets Ther. 12:11325–11338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang
R, Jin Y, Zou C, Chen Y, Wang G, et al: Long non-coding RNA H19
confers 5-Fu resistance in colorectal cancer by promoting
SIRT1-mediated autophagy. Cell Death Dis. 9:11492018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu Y, Zhang X, Tian H, Zhang Z and Tian Y:
Knockdown of long non-coding RNA HOTAIR increases cisplatin
sensitivity in ovarian cancer by inhibiting cisplatin-induced
autophagy. J BUON. 23:1396–1401. 2018.PubMed/NCBI
|
|
9
|
Gao H, Hao G, Sun Y, Li L and Wang Y: Long
noncoding RNA H19 mediated the chemosensitivity of breast cancer
cells via Wnt pathway and EMT process. Onco Targets Ther.
11:8001–8012. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Yu D, Li H, Lv Y and Li S: Long
non-coding RNA UCA1 confers tamoxifen resistance in breast cancer
endocrinotherapy through regulation of the EZH2/p21 axis and the
PI3K/AKT signaling pathway. Int J Oncol. 54:1033–1042.
2019.PubMed/NCBI
|
|
11
|
Xiong H, Ni Z, He J, Jiang S, Li X, He J,
Gong W, Zheng L, Chen S, Li B, et al: LncRNA HULC triggers
autophagy via stabilizing Sirt1 and attenuates the chemosensitivity
of HCC cells. Oncogene. 36:3528–3540. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pachnis V, Belayew A and Tilghman SM:
Locus unlinked to alpha-fetoprotein under the control of the murine
raf and Rif genes. Proc Natl Acad Sci USA. 81:5523–5527. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Müller V, Oliveira-Ferrer L, Steinbach B,
Pantel K and Schwarzenbach H: Interplay of lncRNA H19/miR-675 and
lncRNA NEAT1/miR-204 in breast cancer. Mol Oncol. 13:1137–1149.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ding D, Li C, Zhao T, Li D, Yang L and
Zhang B: LncRNA H19/miR-29b-3p/PGRN axis promoted
epithelial-mesenchymal transition of colorectal cancer cells by
acting on Wnt signaling. Mol Cells. 41:423–435. 2018.PubMed/NCBI
|
|
16
|
Lei Y, Guo W, Chen B, Chen L, Gong J and
Li W: Tumor-released lncRNA H19 promotes gefitinib resistance via
packaging into exosomes in non-small cell lung cancer. Oncol Rep.
40:3438–3446. 2018.PubMed/NCBI
|
|
17
|
Duan S, Li M, Wang Z, Wang L and Liu Y:
H19 induced by oxidative stress confers temozolomide resistance in
human glioma cells via activating NF-κB signaling. OncoTargets
Ther. 11:6395–6404. 2018. View Article : Google Scholar
|
|
18
|
Maheswaran T and Rushbrook SM:
Epithelial-mesenchymal transition and the liver: Role in
hepatocellular carcinoma and liver fibrosis. J Gastroenterol
Hepatol. 27:418–420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fukuda K, Takeuchi S, Arai S, Katayama R,
Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki
T, et al: Epithelial-to-mesenchymal transition is a mechanism of
ALK inhibitor resistance in lung cancer independent of ALK mutation
status. Cancer Res. 79:1658–1670. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gaianigo N, Melisi D and Carbone C: EMT
and treatment resistance in pancreatic cancer. Cancers (Basel).
9:E1222017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun J, Xu Z, Lv H, Wang Y, Wang L, Ni Y,
Wang X, Hu C, Chen S, Teng F, et al: eIF5A2 regulates the
resistance of gastric cancer cells to cisplatin via induction of
EMT. Am J Transl Res. 10:4269–4279. 2018.PubMed/NCBI
|
|
23
|
Dong H, Hu J, Zou K, Ye M, Chen Y, Wu C,
Chen X and Han M: Activation of LncRNA TINCR by H3K27 acetylation
promotes trastuzumab resistance and epithelial-mesenchymal
transition by targeting MicroRNA-125b in breast cancer. Mol Cancer.
18:32019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Malenstein H, Dekervel J, Verslype C,
Van Cutsem E, Windmolders P, Nevens F and van Pelt J: Long-term
exposure to sorafenib of liver cancer cells induces resistance with
epithelial-to-mesenchymal transition, increased invasion and risk
of rebound growth. Cancer Lett. 329:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Wang M, Liang N and Guan L: PDCD2
sensitizes HepG2 cells to sorafenib by suppressing epithelial
mesenchymal transition. Mol Med Rep. 19:2173–2179. 2019.PubMed/NCBI
|
|
26
|
Huang XH, Wang Q, Chen JS, Fu XH, Chen XL,
Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, et al: Bead-based microarray
analysis of microRNA expression in hepatocellular carcinoma:
MiR-338 is downregulated. Hepatol Res. 39:786–794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Que KT, Zhou Y, You Y, Zhang Z, Zhao XP,
Gong JP and Liu ZJ: MicroRNA-31-5p regulates chemosensitivity by
preventing the nuclear location of PARP1 in hepatocellular
carcinoma. J Exp Clin Cancer Res. 37:2682018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu H, Lu S, Yang D, Zhang L, Ye J, Li M
and Hu W: MiR-20a-5p regulates gemcitabine chemosensitivity by
targeting RRM2 in pancreatic cancer cells and serves as a predictor
for gemcitabine-based chemotherapy. Biosci Rep. 39:BSR201813742019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng QP, Du DB, Ming Q, Hu F, Wu ZB and
Qiu S: MicroRNA 494 increases chemosensitivity to doxorubicin in
gastric cancer cells by targeting phosphodiesterases 4D. Cell Mol
Biol (Noisy-le-grand). 64:62–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li DY, Busch A, Jin H, Chernogubova E,
Pelisek J, Karlsson J, Sennblad B, Liu S, Lao S, Hofmann P, et al:
H19 induces abdominal aortic aneurysm development and progression.
Circulation. 138:1551–1568. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Smits G, Mungall AJ, Griffiths-Jones S,
Smith P, Beury D, Matthews L, Rogers J, Pask AJ, Shaw G, VandeBerg
JL, et al: Conservation of the H19 noncoding RNA and H19-IGF2
imprinting mechanism in therians. Nat Genet. 40:971–976. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cai X and Cullen BR: The imprinted H19
noncoding RNA is a primary microRNA precursor. RNA. 13:313–316.
2007. View Article : Google Scholar : PubMed/NCBI
|
